Subretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatments Trials
Alex Willoughby(Duke University), Christopher Dock, Tina Bell, Peggy Gilbert, Trenise Steele, Tori Jones, Jodi Creighton, Stephanie Schindeldecker, Jean Arnwine, Kathyrn Damato, Timothy Crew, Robert G. Ramsay, Kim Bell, Ryan Neist, Polly A. Quiram, John Snater, Ebenezer Daniel(University of Pennsylvania), Holly Cheshier, Sally Arceneaux, Martha Moos, Carmen Chan-Tram, Dwight Selders, Jill Johnson, Herbert L. Cantrill, Neal Oestreich, Shelly Valardi, Julianne Enloe, David Callanan(Texas Retina Associates (United States)), Gui‐Shuang Ying(Philadelphia College of Osteopathic Medicine), Hank A. Aguado, John B. Davies, Lisa Mayleben, Patricia Bradley, Bob Boleman, Lori Coors, Juan E. Grunwald(University of Pennsylvania), Kimberly Cummings, Jessica Tonsfeldt, Sara Beardsley, Cynthia A. Toth(Duke University), Glenn J. Jaffe(Duke University), Maureen G. Maguire(Penn Presbyterian Medical Center), David F. Williams, Sundeep Dev, Edwin H. Ryan, Gary E. Fish, Gennaro Follano, Steven R. Bennett, Robert A. Mittra
Cited by 212
Related Papers
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
|Ophthalmology|2012|1.7k
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial
|The Lancet|2009|857
Diabetic Retinopathy Preferred Practice Pattern®
|Ophthalmology|2019|703
Five-Year Outcomes with Anti–Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration
|Ophthalmology|2016|702
Adalimumab in Patients with Active Noninfectious Uveitis
|New England Journal of Medicine|2016|646